<DOC>
	<DOCNO>NCT00224614</DOCNO>
	<brief_summary>The allograft marrow technique reference ( myélo-ablative ( MA ) condition cyclophosphamide total body irradiation ( TBI ) strong amount ) therapeutic recognize acute myeloid leukaemia ( AML ) adult patient less 55 year , offer chance cure high chemotherapy auto-graft . However , mortality relate traditional graft approximately 30 % 1 year . The recent use non-myélo-ablative graft ( NMA ) , anti-leukaemia effect rest exclusively allogenic effect `` graft-versus-leukaemia '' make possible obtain among patient 55 year complete reemission ( CR ) , survival without relapse comparable traditional allograft among patient 35 year . The major interest NMA graft reduce early mortality relate graft . This reduction significant patient younger , thus bring good survival . There , present hour , prospective comparative study two procedure graft . Taking account result observe NMA graft among patient 55 year , take account toxicity standard graft 35 55 year , essential compare 2 approach among patient counter-indication one , age bracket toxicity traditional graft high .</brief_summary>
	<brief_title>Randomised Prospective Comparison NMA Allograft Traditional Allograft Acute Myeloid Leukaemia</brief_title>
	<detailed_description>Will include CR1 patient good forecast chemotherapy , ( Inv 16 ; ( 8 ; 21 ) ) , patient high risk relapse ( anomaly complex cytogenetics ) . The conditioning MA graft Cyclophosphamide ICT strong amount . NMA graft make accord protocol Seattle ( fludarabine 30 mg/m2/j X 3 ICT 2 Gy ) . The study undertake 12 French center allograft take part protocol ESPARTO EORTC .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Age : 35 55 year complete 2. de novo Acute Myeloid Leukaemia ( AML ) Complete remission ( CR ) 1 , require allograft accord therapeutic protocol ( accord ) patient treat secondary AML myelodysplasy chemotherapy CR1 de novo AML secondary myelodysplasy chemotherapy , CR2 . 3. génoidentical fraternal donor 4. receive , since obtain remission ( 1 2 ) consolidation comprise least 6 bolus Aracytine ( &gt; 500 mg/m2 amount ) least 1 day anthracycline usual amount ( Idarubicin : 12 mg/m2 Daunorubicin 50 80 mg/m2 ) 5 . Signed assent receiver 6 . Signed assent donor 1 . If CR1 : AML T 8,21 inv 16 LAM3 , AML complex anomaly cytogenetics ( = 5 anomaly without relation ) 2 . If CR2 : duration CR1 &lt; 4 month 3 . Acute transformation myeloproliferative syndrome 4 . Former autograft allogreffe 5 . Karnofsky &lt; 50 % 6 . Clearance creatinin &lt; 40 ml/min 7 . Transaminases &gt; 8 N 8 . Any situation contraindicate traditional conditioning allograft , particular : serious cardiopathy , chronic respiratory insufficiency cut pulmonary function least 30 % , fibrose hepatic . 9 . Donor counterindication administration growth promoter general anaesthesia .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>stem cell transplantation</keyword>
	<keyword>reduced-intensity conditioning regimen</keyword>
	<keyword>acute myeloid leukemia</keyword>
</DOC>